Advanced Search

Oncology & Hematology Coding Alert

Reader Question:

Assign J0880 for Non-ESRD

Published on Sun Feb 01, 2004

Question: What tips do you have for reporting J0880?

Michigan Subscriber Answer: Medicare carriers will pay for J0880 (Injection, darbepoetin alfa, 5 mcg) only when the oncologist administers the drug in the office to patients who are not on dialysis and don't have end-stage renal disease (ESRD). Furthermore, payers won't recognize the code if dialysis facilities bill for the code. Physicians often provide the drug to increase red blood cells and prevent anemia.  - Answers to Reader Questions and You Be the Coder were provided by Linda L. Lively, MHA, CCS-P, RCC, CHBME, founder and CEO of American Medical Accounting and Consulting in Marietta, Ga.; and Margaret M. Hickey, MS, MSN, RN, OCN, CORLN, an independent coding consultant based in New Orleans.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All